Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05998460
Other study ID # STUDY00006573
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 2, 2024
Est. completion date August 2025

Study information

Verified date June 2023
Source Georgetown University
Contact Princess M Georges
Phone 2026872117
Email pg763@georgetown.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, parallel-arm randomized controlled pilot study that aims to examine the feasibility and acceptability of the glucose-guided eating (GGE) mobile app and intervention in two populations at risk of chronic disease (postmenopausal women with prediabetes and AYA cancer survivors).


Description:

The primary objectives of the study are to (1) test the feasibility and acceptability of the GGE intervention and companion GGE mobile app and (2) quantify the preliminary effect of GGE on 12-week changes in insulin resistance (IR) and body weight. The secondary objectives of the study are to (1) collect preliminary data on hypothesized mechanisms linking GGE to IR and (2) explore the durability of intervention effects on 24-week changes in body weight.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date August 2025
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: All: 1. Self-reported height and weight that is consistent with a BMI = 27 kg/m2 2. Willing to use a continuous glucose monitor 3. Own smartphone that is compatible with Dexcom CGM. 4. Willingness to commute to GUMC for in-person study visits 5. No active cancer (except for nonmelanoma skin cancer) 6. Less than 5 lbs. weight change in previous 3 months 7. Proficient in speaking and reading English Postmenopausal women with pre-diabetes: 8. Age 18 years and older 9. Diagnosed as having prediabetes. 10. HbA1c (within 3 months) between 5.7% and 6.4% 11. Postmenopausal (defined as reporting no menstrual period for =1 year or a reported history of a total abdominal hysterectomy with oophorectomy) AYA cancer survivors: 12. Current age 21-39 years 13. Previously diagnosed with cancer, with all cancer-related diagnosis chemotherapy and/or radiation completed at least 6 months previously Exclusion Criteria: 1. Unable or unwilling to provide informed consent 2. Clinical history of type 1 or type 2 diabetes 3. Currently receiving anti-diabetics (e.g., insulin, GLP1), oral hypoglycemic agent (e.g., metformin), oral corticosteroids, oral glucocorticoids, beta blockers, hydroxyurea, atypical antipsychotic agents (i.e., Olanzapine, Aripiprazole) or systemic progestin-only contraceptives 4. Current or past history of an eating disorder 5. Self-identify as an overnight eater (defined as eating main meals between 9pm-5am) 6. Have any contraindications for CGM, including: severe allergy to surgical adhesive, being on dialysis, receiving diathermy treatment, or scheduled CT scan or MRI during wear period 7. Growth hormone deficiency, hypoadrenal function, or hypopituitary function

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Glucose-Guided Eating with CGM
The GGE intervention consist of up to four weeks of training to learn to eat when glucose levels are at or below their usual fasting level. Specifically, participants following GGE will self-monitor their glucose levels with an unblinded CGM while using a mobile app (GGE app) that will provide feedback on whether or not to eat. At desired mealtimes participants will enter their current glucose level, rate their perceived hunger, and label the type of hunger they are experiencing (physical, emotional, sensory and practical). Participants following GGE will be instructed by the app to eat when two conditions are met: (a) the desire to eat arises and (b) their glucose levels are at or below a personalized threshold. During the training period, participants are meant to associate feelings of perceived hunger with fasting glucose levels (i.e., physical hunger). After the training period, participants continue to follow GGE without CGM or use of the app.
Other:
CGM only
Comparator participants will use unblinded CGM for up to 4 weeks without the use of the GGE app or any other dietary recommendations.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Georgetown University

References & Publications (2)

Schembre SM, Jospe MR, Bedrick EJ, Li L, Brewster AM, Levy E, Dirba DD, Campbell M, Taylor RW, Basen-Engquist KM. Hunger Training as a Self-regulation Strategy in a Comprehensive Weight Loss Program for Breast Cancer Prevention: A Randomized Feasibility Study. Cancer Prev Res (Phila). 2022 Mar 1;15(3):193-201. doi: 10.1158/1940-6207.CAPR-21-0298. — View Citation

Schembre SM, Jospe MR, Giles ED, Sears DD, Liao Y, Basen-Engquist KM, Thomson CA. A Low-Glucose Eating Pattern Improves Biomarkers of Postmenopausal Breast Cancer Risk: An Exploratory Secondary Analysis of a Randomized Feasibility Trial. Nutrients. 2021 Dec 16;13(12):4508. doi: 10.3390/nu13124508. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Population-specific accrual Population-specific accrual will reflect rates of study enrollment and will be defined as number of participants consented to the number of individuals who are determined to be eligible. Week 0
Primary Population-specific retention rates Population-specific retention rates will reflect the proportion of enrolled participants who complete the study. Week 12
Primary GGE app usability The app usability will be assessed using the 10-item System Usability Scale. SUS scores have a range of 0 to 100 with 100 representing greatest usability. Week 12
Primary GGE intervention acceptability GGE intervention acceptability will be assessed with a study specific survey (collected from participants randomized to the GGE intervention only). Week 12
Primary GGE adherence GGE adherence will be quantified as percent of reported eating events occurring at or below personalized glucose thresholds/personalized average fasting glucose levels that is collected using the GGE app (collected from participants randomized to the GGE intervention only-during use of the GGE app only). Weeks 1-4
Secondary Changes in body weight Changes in body weight will be measured using calibrated digital scales (measured in kilograms). Weeks 0-12 and Weeks 12-24
Secondary Changes in insulin resistance (HOMA-IR) Changes in insulin resistance will be measured as homeostatic model assessment for insulin resistance (HOMA-IR). It will be computed from fasting insulin and fasting glucose (fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5). Weeks 1-12
Secondary Changes in glycemic variability Changes in glycemic variability will be assessed from CGM data using the freely accessible EasyGV software available from the University of Oxford (https://www.phc.ox.ac.uk/research/resources/easygv). Weeks 1-12
Secondary Changes in oxidative stress Changes in oxidative stress will be measured as 8-isoprostane from spot urine. Weeks 1-12
Secondary Changes in the soluble receptor for advanced glycation end-products (sRAGE) Changes the sRAGE was measured in serum by ELISA. Weeks 1-12
See also
  Status Clinical Trial Phase
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Completed NCT03188263 - Morning Light Treatment to Improve Glucose Metabolism N/A
Recruiting NCT03821961 - 18F-FDOPA PET/CT Imaging in Patients Undergoing Metabolic Surgery N/A
Completed NCT04303468 - Intervention With a GABA Supplement in Prediabetics N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT01910051 - Explorative Assessment of Biomarkers in Overweight and Obese Subjects
Completed NCT03527368 - The Time-Restricted Intake of Meals Study N/A
Not yet recruiting NCT06453278 - (DDS) in India: a Screening Tool to Identify Prediabetes and Undiagnosed Type 2 Diabetes in Dental Settings
Completed NCT03865342 - Prevention of Diabetes Using Mobile-enabled, Virtual Delivery of the National Diabetes Prevention Program N/A
Completed NCT02899390 - Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes N/A
Suspended NCT03240978 - Exercise Intervention for the Prevention of Prediabetes in Overweight Chinese N/A
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Completed NCT01436916 - Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus Phase 4
Completed NCT01432509 - Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord) N/A
Completed NCT00990184 - Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes) Phase 3
Completed NCT00886340 - A Lifestyle Change Program to Prevent Type 2 Diabetes Phase 2